Corestem is a biopharmaceutical company that researches and commercializes stem cell technology.


Pipeline Overview
Neurological Disease Cell Type Pre-clinical Phase I Phase II Phase III
ALS: Amyotrophic Lateral Sclerosis Auto BM-MSC
Neuronata-R® inj.
CA: Cerebellar Ataxia Allo BM-MSC
NMO: Neuromyelitis Optica Allo BM-MSC
PD: Parkinson’s disease iPSC
Autoimmune Disease Cell Type Pre-clinical Phase I Phase II Phase III
SLE: Systemic Lupus Erythematosus Allo BM-MSC
Fibrosis EVs

R&D focused on Neurological & Autoimmune Incurable Disease

Neurological Diseases

Medical conditions in which motor control, perception, sensation, and the autonomic nervous system functions abnormally due to the death or loss of nerve cells.

  • Amyotrophic Lateral Sclerosis
  • Multiple Sclerosis
  • Parkinson Disease
Autoimmune Diseases

A pathological state in which the body’s immune system attacks healthy cells or tissues. Symptoms and types of autoimmune disease very depending on which parts of the body are attacked or destroyed by immune cells.

  • Systemic Lupus Erythematosus
  • Optic Neuritis
Rare disease

At first we are offering stem cell treatment for a disease area that’s no cure and patients suffering from incurable and rare disease. We developed the world’s first stem cell therapeutic product for ALS (Amyotrophic Lateral Sclerosis) name of NEURONATA-R, is an autologous bone marrow mesenchymal stem cell (autologous BM-MSC) therapy.

Corestem is dedicated the development of a treatment for rare disease area such as ALS and Lupus where has higher market potential, faster growth rate, less competitor, and expertise track of orphan drug. As the characteristic advantage of rare disease, our strategy focuses on niche markets; high-value drugs for rare diseases of low prevalence, but for which a high return on investment could be reaped